CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Artemisinin / ArtesunateWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug2375 Sulfonatoporphyrin(TPPS) plus Sunlight exposure. Wiki 1.00
drug2276 SnPP Protoporphyrin plus Sunlight exposure Wiki 0.58
drug2950 placebo Wiki 0.27

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongoing clinical trials evaluating potential treatments Drugs used to treat malaria infection has shown to be beneficial for many other diseases, including viral infections. In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stable positive swab COVID-19 patients. Investigators are hypothesizing that due to the antiviral properties of this drug it will help as a treatment for the COVID -19 patients. In improving their condition and clearing the virus load,

NCT04387240 Covid 19 Positive Corona Virus Infection Drug: Artemisinin / Artesunate Other: placebo
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: absence of the virus shedding evidenced by negative swabs

Measure: length of stay in hospital

Time: within the first 6 days intervention

Secondary Outcomes

Description: reduction of morbidity and mortality

Measure: number of ICU admission

Time: 14 days

Description: finding the time that the symptoms disappear

Measure: resolution of symptoms

Time: 6 days - 10 day


No related HPO nodes (Using clinical trials)